Assessing real-world effectiveness of therapies: what is the impact of incretin-based treatments on hospital use for patients with type 2 diabetes?
Fiche du document
22 octobre 2022
- handle: 10670/1.g6xqgb
- hal: hal-03830798
- doi: 10.1186/s13561-022-00397-5
- PUBMED: 36272025
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1186/s13561-022-00397-5
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36272025
http://creativecommons.org/licenses/by/ , info:eu-repo/semantics/OpenAccess
Sujets proches
TherapyCiter ce document
Clémence Bussière et al., « Assessing real-world effectiveness of therapies: what is the impact of incretin-based treatments on hospital use for patients with type 2 diabetes? », HAL-SHS : économie et finance, ID : 10.1186/s13561-022-00397-5
Métriques
Partage / Export
Résumé
BACKGROUND: Managing type 2 diabetes represents a major public health concern due to its important and increasing prevalence. Our study investigates the impact of taking incretin-based medication on the risk of being hospitalized and the length of hospital stay for individuals with type 2 diabetes. METHOD: We use claim panel data from 2011 to 2015 and provide difference-in-differences (DID) estimations combined with matching techniques to better ensure the treatment and control groups’ comparability. Our propensity score selects individuals according to their probability of taking an incretin-based treatment in 2013 (N = 2,116). The treatment group includes individuals benefiting from incretin-based treatments from 2013 to 2015 and is compared to individuals not benefiting from such a treatment but having a similar probability of taking it. RESULTS: After controlling for health-related and socio-economic variables, we show that benefiting from an incretin-based treatment does not significantly impact the probability of being hospitalized but does significantly decrease the annual number of days spent in the hospital by a factor rate of 0.621 compared with the length of hospital stays for patients not benefiting from such a treatment. CONCLUSION: These findings highlight the potential implications for our health care system in case of widespread use of these drugs among patients with severe diabetes.